Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4‐year results from the randomised EXIST‐1 and EXIST‐2 studies
Tags: Afinitor®, cancer, immunosuppressant, kinase inhibitor, mammalian target of rapamycin (mTOR) inhibitor, sirolimus derivative, Zortress®
BASi Method Number SAP.038
Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.
